Cargando…

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target

Detalles Bibliográficos
Autores principales:	Govindpani, Karan, Vinnakota, Chitra, Waldvogel, Henry J., Faull, Richard L., Kwakowsky, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034279/ https://www.ncbi.nlm.nih.gov/pubmed/31823877 http://dx.doi.org/10.4103/1673-5374.270306

Ejemplares similares

Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?
por: Govindpani, Karan, et al.
Publicado: (2019)

Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
por: Govindpani, Karan, et al.
Publicado: (2017)

Gamma-aminobutyric acid A receptors in Alzheimer's disease: highly localized remodeling of a complex and diverse signaling pathway
por: Kwakowsky, Andrea, et al.
Publicado: (2018)

Therapeutic potential of alpha 5 subunit containing GABA(A) receptors in Alzheimer’s disease
por: Kwakowsky, Andrea, et al.
Publicado: (2021)

Impaired Expression of GABA Signaling Components in the Alzheimer’s Disease Middle Temporal Gyrus
por: Govindpani, Karan, et al.
Publicado: (2020)

iGluR expression in the hippocampal formation, entorhinal cortex, and superior temporal gyrus in Alzheimer’s disease
por: Yeung, Jason HY, et al.
Publicado: (2022)

An α5 GABAA Receptor Inverse Agonist, α5IA, Attenuates Amyloid Beta-Induced Neuronal Death in Mouse Hippocampal Cultures
por: Vinnakota, Chitra, et al.
Publicado: (2020)

The effects of amyloid-beta on hippocampal glutamatergic receptor and transporter expression
por: Kwakowsky, Andrea, et al.
Publicado: (2020)

Is EAAT2 a potential therapeutic intervention target for Alzheimer’s disease?
por: Wood, Oliver WG, et al.
Publicado: (2023)

Neuroprotective Effect of Caffeine in Alzheimer’s Disease
por: M Yelanchezian, Y Mukish, et al.
Publicado: (2022)

Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer’s Disease
por: Kwakowsky, Andrea, et al.
Publicado: (2016)

Current and Possible Future Therapeutic Options for Huntington’s Disease
por: Ferguson, Mackenzie W., et al.
Publicado: (2022)

The Role of Microglia and Astrocytes in Huntington’s Disease
por: Palpagama, Thulani H., et al.
Publicado: (2019)

Metabotropic glutamate receptor 1 alpha: a unique receptor variant with variable implications for Alzheimer’s disease pathogenesis
por: Yeung, Jason HY, et al.
Publicado: (2023)

Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?
por: Mills, Zoe B., et al.
Publicado: (2023)

Beta-Amyloid (Aβ(1-42)) Increases the Expression of NKCC1 in the Mouse Hippocampus
por: Lam, Patricia, et al.
Publicado: (2022)

Glutamatergic receptor expression changes in the Alzheimer's disease hippocampus and entorhinal cortex
por: Yeung, Jason H. Y., et al.
Publicado: (2021)

EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review
por: Wood, Oliver W. G., et al.
Publicado: (2022)

EAAT2 Expression in the Hippocampus, Subiculum, Entorhinal Cortex and Superior Temporal Gyrus in Alzheimer’s Disease
por: Yeung, Jason H. Y., et al.
Publicado: (2021)

Dysfunction of axonal transport in normal-tension glaucoma: a biomarker of disease progression and a potential therapeutic target
por: Hirooka, Kazuyuki, et al.
Publicado: (2020)

mGluR1α expression in the hippocampus, subiculum, entorhinal cortex and superior temporal gyrus in Alzheimer’s disease
por: Yeung, J.H.Y., et al.
Publicado: (2022)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

Sex- and age-related changes in GABA signaling components in the human cortex
por: Pandya, Madhavi, et al.
Publicado: (2019)

Diagnostic and therapeutic potential of exosomal miRNAs in Alzheimer’s disease
por: Manna, Ida, et al.
Publicado: (2021)

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease
por: Li, Zhongqi, et al.
Publicado: (2021)

CD34(+) progenitor cells as diagnostic and therapeutic targets in Alzheimer’s disease
por: Romaus-Sanjurjo, Daniel, et al.
Publicado: (2022)

Targeting calcium signaling in Alzheimer’s disease: challenges and promising therapeutic avenues
por: Song, LinLin, et al.
Publicado: (2023)

Activation of tyrosine phosphatases in the progression of Alzheimer's disease
por: Stewart, Alexandre F. R., et al.
Publicado: (2020)

Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease
por: Tao, Qing-Qing, et al.
Publicado: (2022)

GABA(A) Receptors Are Well Preserved in the Hippocampus of Aged Mice
por: Palpagama, Thulani H., et al.
Publicado: (2019)

Microparticles as Novel Biomarkers and Therapeutic Targets in Coronary Heart Disease
por: Zhou, Bo-Da, et al.
Publicado: (2015)

Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
por: Weninger, Stacie, et al.
Publicado: (2020)

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease
por: Monteiro, Kadja Luana Chagas, et al.
Publicado: (2020)

Intrathecal corticosteroids might slow Alzheimer’s disease progression
por: Alisky, Joseph Martin
Publicado: (2008)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Role of presynaptic calcium stores for neural network dysfunction in Alzheimer's disease
por: Lerdkrai, Chommanad, et al.
Publicado: (2018)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders
por: Lam, Patricia, et al.
Publicado: (2023)

On the horizon—the value and promise of the global pipeline of Alzheimer's disease therapeutics
por: Cole, Michael A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oerc00blgegr5r7ec7qcruqm9r